Inclusion Criteria:

- The patients must have a histological diagnosis of aggressive non-Hodgkin’s lymphoma
including the following sub-categories of the WHO classification:

- Diffuse large B-cell lymphoma and its variants (immunoblastic, Burkitt-like,
sclerosis of mediastinum, large B-cell MALT, rich in T-cells and anaplastic
B-cell lymphoma)

- Peripheral T-cell lymphoma

- Anaplastic lymphoma of large T-cells /null cells

- Patients are eligible if they have documented evidence of progression after prior
first-line chemotherapy containing anthracyclines associated or not with Rituximab.
Patients with refractory disease to first line of treatment are also eligible.

- ECOG PS (performance status) less than or equal to 2

- Presence of bidimensionally measurable disease in accordance with WHO criteria.

Exclusion Criteria:

- Involvement of the CNS.

- Any medical condition which contraindicates the degree of hydration required for the
safe use of cisplatin.

- Intermediate degree lymphoma derived from the malignant transformation of a previous
low-grade lymphoma.

- Active infection (in the opinion of the investigator).